Table 2.

Analysis of puncture-free survival in different subgroups (pivotal trial)

		Catumaxomab (n = 170)		Control (n = 88)
		n	Median PunFS (days)	n	Median PunFS (days)
Primary tumour	Ovarian-cancer	85	52	44	11
	All non-ovarian cancer	85	37	44	14
	Gastric cancer	46	44	20	15
Distant metastasis	No	70	48	32	11
	Yes	99	44	56	13
Liver metastasis	No	133	49	68	14
	Yes	36	27	20	9
Age range	>median	84	44	44	11
	≤median	86	48	44	13
Total serum protein	>median	81	55	43	13
	≤median	88	31	44	11